

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A consultee commented that not recommending this technology would result in significant inequality in care in the UK compared to the rest of the world. During consultation unmet need for immunotherapy for people with gastric cancer was noted. These were not considered to be equalities issues as the preliminary recommendations did not restrict access to nivolumab for a particular group of people with protected characteristics. In the FAD nivolumab is recommended for all people with gastrooesophageal cancer covered by the marketing authorisation for nivolumab

A consultee noted that inequalities in health resulting from late diagnosis in some groups were apparent in stomach cancer. This was not considered to be an equality issue which could be addressed by the appraisal committee's recommendations.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

Issue date: January 2023

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, section 3.16 states that no equality issues were identified.

Approved by Associate Director (name): Janet Robertson

Date: 08 November 2022